Business Profile | Business Model
Bioniche Life Sciences operates three global business divisions: Human Health, Animal Health and One Health.
Bioniche Therapeutics Corp.
Bioniche Therapeutics Corp. is responsible for scientific discovery, pre-clinical research, clinical development, regulatory submissions and commercialization of therapeutic products for use in human medicine. Using two platform technologies: Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) and oligonucleotides, our R&D initiatives focus on the areas of cancer and immunomodulation. Therapeutics’ product development candidates include MCNA for treatment of bladder cancer, intraperitoneal cancers (ovarian, colorectal), and metastatic cancers, and a combination of MCNA and hyaluronan for treatment of prostate cancer.
More on Human Health research & development
Bioniche Animal Health
Bioniche Animal Health was established in 1979 to develop vaccines and other pharmaceutical products for the preventive health management of animal diseases. Now the largest Canadian-owned animal health company, Bioniche Animal Health has a large product portfolio that can be categorized in three major groups: reproduction and embryo transfer, immunology and vaccine products. Folltropin®-V, the company's lead product, is the highest quality and best-selling follicle stimulating hormone (FSH) in the animal health marketplace worldwide. Folltropin®-V is used in the embryo transfer industry to induce superovulation in cattle and sheep. The company's research and development program has provided veterinarians and animal producers with a wide range of animal vaccines with proven safety profiles for use in cattle, swine, equine and companion animals.
Learn more about Bioniche Animal Health
One Health, the newest division of Bioniche Life Sciences Inc., is responsible for researching, developing, manufacturing, and marketing veterinary biopharmaceutical products to address diseases in livestock which may have an effect on human health.
The leading One Health initiative is the development and commercialization of a new vaccine for the reduction of E. coli O157:H7 bacteria in cattle. This new vaccine is designed to reduce the colonization of E. coli O157:H7 bacteria in cattle and the prevalence of the bacteria in cattle manure, thereby reducing potential contamination in the environment, ground water, and cattle processing plants. The Division is also working on the development of other products to address livestock diseases that may affect food and water supplies.
Learn more about our E. coli O157:H7 cattle vaccine – trademarked Econiche® - now authorized by the Canadian Food Inspection Agency (CFIA) for distribution to Canadian veterinarians:
Background on Econiche®
More About E. coli O157:H7 Infection
Animal Health and Food Safety Vaccine Manufacturing Centre
The Company has constructed an Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario. The construction project was completed at the end of March, 2011, after which commissioning and validation began.
The facility includes air filtration to supply clean rooms and biocontainment rooms, autoclaving, fermentation, micro- and ultra-filtration systems, filling lines, packaging equipment, QA/QC controls, pure-steam systems, sterile product filtration, water for injection systems, cold storage, worker health and safety management and others.
The facility has been financed by repayable contributions from the Ontario Ministry of Economic Development & Trade's Advanced Manufacturing Investment Strategy (C$10 million), the Business Development Bank of Canada (C$5 million), Industry Canada's Industrial Technologies Office (C$7.6 million) and Agriculture and Agri-Food Canada's Agri-Opportunities Program (C$5 million).
July 9, 2013 Validation Update